The 9th China Healthcare Investment Conference (CHIC) was held on March 28-29, 2018 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, presented TenNor’s recent progress to the conference (please click this link for the presentation: TENNOR 9th CHIC Presentation).

CHIC is the premier investment conference in China. In 2010, recognizing that the healthcare reform and industry growth was spurring a new wave of emerging Chinese healthcare companies, a group of investors led the efforts to organize China Healthcare Investment Conference. This prestigious event has since grown into the most powerful platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the industry.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com